Table 5.
Serum SOCS1, TAB2, and Foxp3 level in cachectic and non-cachectic pancreatic and NSCL cancer patients and cachexia severity.
| Variable | SOCS1 (ng/ml) | TAB2 (ng/ml) | Foxp3 (ng/ml) | ||
|---|---|---|---|---|---|
| Pancreatic cancer patients | |||||
| Non-cachectic (n = 20) | 9.3 (7–26) | 6.3 (2.0–8.4) | 16 (5–30) | ||
| Cachectic (n = 48) | 5.6 (3.3–8.6) | 6.2 (4.8–13.0) | 8.9 (6.5–96.0) | ||
| Statistics | U: 185 p = 0.002** |
U: 262 p = 0.06 |
U: 49 p = 0.0001*** |
||
| Cachexia severity | |||||
| Pre-cachexia (n = 14) | 5.6 (3.2–6.5) | 6.5 (5.2–8.4) | 16 (7–35) | ||
| Cachexia (n = 17) | 5.2 (4.2–8.6) | 6.3 (5.9–8.4) | 14.5 (6–33) | ||
| Refractory (n = 17) | 5.8 (3.7–7.4) | 5.6 (2.6–7.8) | 11.3 (5.6–30) | ||
| Statistics | F: 1.1 p = 0.34 |
F: 0.2 p = 0.8 |
F: 5.3 p = 0.008** |
||
| NSCL cancer patients | |||||
| Non-cachectic (n = 10) | 10.9 (4.0–14) | 9.2 (7.0–20) | 8.8 (6.0.11) | ||
| Cachectic (n = 18) | 5.8 (4.0–9.2) | 8.0 (5.6 –29) | 6.8 (4.6–9.7) | ||
| Statistics | U: 39 p = 0.01** |
U: 57 p = 0.12 |
U: 35 p = 0.03* |
||
| Cachexia severity score | |||||
| Pre-cachexia (n = 9) | 7.2 (4.2–9.2) | 10 (5.6–29) | 7.4 (4.6–9.7) | ||
| Cachexia (n = 7) | 5.5 (4.5–6.8) | 7.5 (7.0–9.0) | 6.9 (4.9–7.8) | ||
| Refractory (n = 2) | 5.2 (4.8–5.4) | 6.4 (6.0–6.8) | NA | ||
| Statistics | F: 2.3 p = 0.12 |
F: 1.2 p = 0.34 |
F: 1.2 p = 0.33 |
||
Data are given as median (minimum–maximum). Statistical analysis was carried out using the Mann–Whitney test and ANOVA test followed by Bonferroni’s post-hoc test; p ≤ 0.05.
F, ANOVA test value; Foxp3, forkhead box P3; n, number; SOCS1, suppressor of cytokine signaling 1; TAB2, TAK1-associated Binding Protein 2; U, Mann-Whitney; NSCL, non-small cell lung.
*Significant difference at p < 0.05.
**Significant difference at p ≤ 0.01.
***Significant difference at p ≤ 0.001.